IntegraGen and the Institut Pasteur signed an agreement for high-throughput sequencing in the field of Microbiology. IntegraGen will be responsible for the technical and operational implementation of high-throughput sequencing activities for use by the microbiology experts at the National Reference Center (NRC) at the Institut Pasteur. High-throughput sequencing will be the reference tool for analysis, surveillance and diagnostic activities associated with the above in line with the public health mission of the Institut.

The Institut Pasteur will rely on the expertise and experience of IntegraGen to help ensure optimal quality of results returned via high-throughput sequencing. IntegraGen will also help reduce delays in obtaining sequencing results and increase the flexibility of the business while optimizing the operational costs of reagents. Additionally, IntegraGen will develop management software tailored to the internal needs of the Institut Pasteur.

The primary objective of the partnership between the Institut Pasteur and IntegraGen is to increase access to the latest generation of sequencing technologies for the fifteen NRCs and the Institute’s microbiology collection with the additional goal of establishing reference tools for the typing of bacterial, viral, and fungal strains.

ADVERTISEMENT

Professor Christian Bréchot, General Manager of the Institut Pasteur, stated “Being at the heart of infectious disease surveillance issues worldwide, the Institut Pasteur must equip its laboratories with the best available technology. Having access to IntegraGen’s know-how in high-throughput sequencing is a major asset to reinforce our mobilization abilities and to ensure our mission for public health at the highest level.

Institut Pasteur is an international research institute of excellence with a mission to advance science, medicine and public health, while also aiding in the prevention and the fight against infectious diseases through research, education and public health actions.

Operating the high-throughput sequencing activities for microbiology at the Institut Pasteur, a world leader in the field of medical research, further demonstrates IntegraGen’s ability to provide high quality next generation sequencing services to researchers and reinforces the awareness of the expertise the company has developed in this field since establishing our Genomic Services business in 2008,” stated Bernard Courtieu, CEO of IntegraGen.

This agreement represents an opportunity for IntegraGen to expand its genomics business and to continue to grow its revenues, which just experienced a 12% increase in 2014. Check out its profile and other interesting biotech companies on Labiotechmap.com.

Previous post

Alzheimer's treatment: an Overview

Next post

Epigenomics' proColon, the non-invasive blood-based test for colorectal cancer

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.